BRIEF: XtalPi acquires British chiral molecule developer
AI drug discovery company XtalPi Holdings Ltd. (2228.HK) said on Thursday it has acquired Liverpool ChiroChem Technologies Ltd. (LCC), a developer of novel molecules specializing in chiral molecules. It did not disclose…
NEWS WRAP: Surging Xtalpi seizes on tech rally to raise $267 million
The Tencent-backed AI drug developer announced a major new fundraising as it steps up its AI project development By Teri Yu AI drug discovery company XtalPi Holdings Ltd. (2228.HK) announced…
BRIEF: XtalPi shares surge on Microsoft China partnership
AI pharmaceutical company XtalPi Holdings Ltd. (2228.HK) on Monday announced it has entered into a strategic cooperation memorandum with Microsoft China for new drug and materials development. Under the tie-up, the…
InSilico seeks IPO boost to get AI drugs over the line
The drug developer has raised around $400 million in seven rounds of financing. But after burning through cash, the company needs fresh capital to sustain its work on AI-assisted drugs…
RELATED ARTICLES
-
NEWS WRAP: Surging Xtalpi seizes on tech rally to raise $267 million
2228.HK
- RNA drug developer Ribo Life targets fresh funding channel
- BRIEF: Shein London IPO approved by British financial regulator
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
Joinn Labs undermined by AI as FDA phases out animal drug testing
6127.HK 603127.SHG
